Evidence map›Paper›PMID 40188293›Full record

ArticleBritish journal of cancer2025

Development of radiomics-based models on mammograms with mass lesions to predict prognostically relevant characteristics of invasive breast cancer in a screening cohort.

Jim Peters, Merle M van Leeuwen, Nikita Moriakov, Jos A A M van Dijck, Ritse M Mann, Jonas Teuwen, Esther H Lips, Alexandra W van den Belt-Dusebout, Jelle Wesseling, Bas B L Penning de Vries and 4 more

Abstract read
In one paragraph

Article in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jim PetersDepartment IQ Health, Radboud University Medical Center, Nijmegen, Netherlands. Jim.Peters@radboudumc.nl.ORCID http://orcid.org/0000-0002-6115-9678
Merle M van LeeuwenDivision of Molecular Pathology, Netherlands Cancer Institute (NKI), Amsterdam, Netherlands.
Nikita MoriakovDepartment of Radiation Oncology, Netherlands Cancer Institute (NKI), Amsterdam, Netherlands.
Jos A A M van DijckDepartment IQ Health, Radboud University Medical Center, Nijmegen, Netherlands.
Ritse M MannDepartment of Radiology, Netherlands Cancer Institute (NKI), Amsterdam, Netherlands.
Jonas TeuwenDepartment of Radiation Oncology, Netherlands Cancer Institute (NKI), Amsterdam, Netherlands.
Esther H LipsDivision of Molecular Pathology, Netherlands Cancer Institute (NKI), Amsterdam, Netherlands.ORCID http://orcid.org/0000-0003-3488-4935
Alexandra W van den Belt-DuseboutDivision of Molecular Pathology, Netherlands Cancer Institute (NKI), Amsterdam, Netherlands.ORCID http://orcid.org/0000-0002-7860-8839
Jelle WesselingDivision of Molecular Pathology, Netherlands Cancer Institute (NKI), Amsterdam, Netherlands.ORCID http://orcid.org/0000-0002-8940-2676
Bas B L Penning de VriesJulius Center for Health Sciences and Primary Care, UMC Utrecht, University Utrecht, Utrecht, Netherlands.
Sarah VerboomDepartment of Medical Imaging, Radboud University Medical Center, Nijmegen, Netherlands.
Nico KarssemeijerDepartment of Medical Imaging, Radboud University Medical Center, Nijmegen, Netherlands.
Sjoerd G EliasJulius Center for Health Sciences and Primary Care, UMC Utrecht, University Utrecht, Utrecht, Netherlands.
Mireille J M BroedersDepartment IQ Health, Radboud University Medical Center, Nijmegen, Netherlands.ORCID http://orcid.org/0000-0002-8741-8148

Funding

KWF Kankerbestrijding (Dutch Cancer Society) 11835
6 · The paper itself

Abstract

backgroundOptimizing breast-screening performance involves minimizing overdiagnosis of prognostically favorable invasive breast cancer (IBC) that does not need immediate recall and underdiagnosis of prognostically unfavorable IBC that is not recalled timely. We investigated whether mammographic features of masses predict prognostically relevant IBC characteristics.

methodsIn a screening cohort, we obtained pathological information of 1587 IBCs presenting as a mass through the nationwide cancer registry and pathology databank. We developed models based on mammographic tumor appearance to predict whether IBC was prognostically favorable (T1N0M0 luminal A-like) or unfavorable. Models were based on 1095 positive screening mammograms (possible overdiagnosis), or on 603 last negative mammograms with in retrospect visible masses (possible underdiagnosis). We calculated performance metrics using cross-validation.

results23.5% of masses were prognostically favorable IBC. Using 1095 positive mammograms, the model's predictions to have prognostically favorable IBC (10th-90th percentile range 8.7-47.0%) yielded AUC 0.75 (SD across repeats 0.01), slope 1.16 (SD 0.07). Performance in 603 last negative screening mammograms with masses was poor: AUC 0.60 (SD 0.02), slope 0.85 (SD 0.28).

conclusionsMammography-based models from masses representing IBC at time of recall (possible overdiagnosis) predict prognostically relevant characteristics of IBC. Models based on in retrospect visible masses (possible underdiagnosis) performed poorly.

Indexed as

Breast NeoplasmsMammographyAdultAgedCohort StudiesEarly Detection of CancerFemaleHumansMiddle AgedNeoplasm InvasivenessPrognosisRadiomics

Identifiers

PMID40188293
PMCPMC12120084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.